
ALD Leads Steatotic Liver Disease Transplant Listings, With Leandro Sierra, MD
UNOS data on 82,014 candidates show ALD accounted for 39.0% of steatotic liver disease transplant listings from 2014 to 2024.
Leandro Sierra, MD, an internal medicine resident at Cleveland Clinic, presented the analysis, which received an ACG Presidential Poster Award, in Nashville, Tennessee. In an interview with HCPLive, Sierra discussed the changing distribution of steatotic liver disease among transplant candidates, regional differences, and potential factors contributing to the trends.
Changing Steatotic Liver Disease Nomenclature and Transplant Trends
In 2023, a multisociety consensus introduced an updated nomenclature for steatotic liver disease, encompassing MASLD, ALD, and metabolic dysfunction and alcohol-associated liver disease (MetALD).² The classification provided a framework for examining how different etiologies contribute to liver transplant waitlisting.
Sierra explained the investigators were interested in changes over the past decade, including the COVID-19 pandemic, advances in
“There have been other events in the last decade that can change how these etiologies behave. We had the COVID-19 pandemic 6 years ago, the introduction of the cure for hepatitis C, and the advancements of the GLP-1s that are now widely used,” Sierra said. “These events can change the trends in multiple things in medicine, and one of those is liver transplantation.”
The investigators sought to characterize changes in waitlisting patterns and transplant outcomes across the 3 steatotic liver disease subtypes.
UNOS Analysis Includes 82,014 Transplant Candidates
Investigators conducted a retrospective analysis of United Network for Organ Sharing (UNOS) registry data involving 82,014 candidates with steatotic liver disease listed for liver transplantation between 2014 and 2024.¹
Candidates were categorized as having ALD, MASLD, or MetALD. The analysis examined temporal trends, patient characteristics at listing, geographic differences, and waitlist outcomes.
ALD accounted for 39.0% of candidates, followed by MASLD at 36.5% and MetALD at 24.5%.¹
MASLD represented the largest proportion of steatotic liver disease listings before 2020, when ALD overtook it.¹
“The gap between ALD and MASLD is actually getting wider and wider,” Sierra said.
ALD Candidates Were Younger at Waitlisting
Patients listed with ALD were younger than those with MASLD, with a mean age of 51.9 versus 59.6 years.¹ ALD candidates also had higher Model for End-Stage Liver Disease (MELD) scores at listing, indicating greater liver disease severity at the time of waitlisting.
Geographic differences were also observed. In Colorado, ALD accounted for 56.7% of steatotic liver disease listings, the greatest reported proportion among states included in the analysis.¹
These findings highlight differences in the characteristics and distribution of patients reaching the liver transplant waitlist, although the registry analysis cannot establish the underlying causes of these patterns.
Potential Contributors to Changing Waitlist Patterns
Sierra discussed 2 possible explanations for the increasing proportion of ALD listings.
The first was
The second involved the expanding use of GLP-1 receptor agonists, which Sierra noted can improve obesity, diabetes, and hypertension, conditions closely tied to MASLD.
However, neither explanation was directly evaluated in the registry analysis. The findings do not establish whether pandemic-related drinking patterns or GLP-1 receptor agonist use contributed to the observed changes in waitlist composition.
Sierra identified further examination of these potential contributors as an area for future research.
The findings describe a shift in the distribution of steatotic liver disease etiologies among US transplant candidates, with ALD accounting for a growing proportion of listings since 2020.
Editor’s Note: Sierra reported no relevant disclosures.
References
Sierra L, Gakhoury B, Parraga X, et al. The Rise of Alcohol-Associated Liver Disease as the Leading Indication for Liver Transplant Waitlisting Among Patients With Steatotic Liver Disease. Poster presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN. Poster P3946.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520
Related to this article








